Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study

Authors: Alcocer, L.1; Fernandez-Bonetti, P.2; Campos, E.1; Dominguez-Henkel, R.3; DE La Fuente, J.J.3; Segovia-Ayala, C.3

Source: International Journal of Clinical Practice, Volume 58, Supplement 145, December 2004 , pp. 23-28(6)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Summary

The efficacy and safety of once-daily telmisartan 80 mg vs. once-daily enalapril 20 mg in the treatment of essential hypertension were evaluated in a multicentre, single-blind, placebo-controlled, randomised trial. In total, 68 patients (49 females, 19 males) with mild-to-moderate hypertension, defined as morning supine systolic blood pressure (SBP) 141-149 mmHg, diastolic blood pressure (DBP) 95-114 mmHg, were enrolled. After a 4-week placebo run-in phase, patients were randomly assigned to treatment with telmisartan or enalapril administered once daily in the morning for 8 weeks. No statistically significant differences were found in the baseline characteristics of patients in either group. Both SBP and DBP were decreased in both treatment groups, but the reductions were statistically different in favour of telmisartan (SBP, p = 0.013; DBP, p = 0.002). The incidence of adverse effects was lower in the telmisartan group, with the absence of cough. In conclusion, telmisartan is more effective and better tolerated than enalapril for the treatment of hypertension and has the advantage that it does not cause cough.

Keywords: Telmisartan; angiotensin II receptor blocker; enalapril; angiotensin-converting enzyme inhibitor; antihypertensives; hypertension

Document Type: Research article

DOI: 10.1111/j.1742-1241.2004.00406.x

Affiliations: 1: Cardiology Service, Hospital General de Mexico, Mexico, DF 2: Cardiology Service, Hospital de Jesus, IAP 3: Medical Department, Boehringer Ingelheim Promeco, Mexico

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$44.84 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A